Lonza Acquires UCB-Bioproducts
Lonza propelled to peptides leader position via acquisition of UCB-Bioproducts. This division, with approximately 300 employees, is located in Braine-l'Alleud just outside of Brussels.
Lonza has announces the successful completion of the acquisition of UCB-Bioproducts in Brussels (Belgium) on 28 February 2006. Lonza, a global peptide custom manufacturer, has acquired the peptide manufacturing division “Bioproducts” from UCB for an amount of € 120 million. This division, with approximately 300 employees, is located in Braine-l'Alleud just outside of Brussels.
By uniting the two peptide businesses, Lonza says it has become the leading and sole contract manufacturer with a historically successful track record of providing Active Pharmaceutical Ingredients (API) from any of the three peptide technologies (liquid phase peptide synthesis, solid phase peptide synthesis and recombinant technology).
This acquisition provides Lonza with a site having global reach in peptides, world leading process development and production expertise to serve its customer base. Lonza-Braine perfectly complements the other Lonza sites in Visp (Switzerland), Riverside Conshohocken (United States) and Kourim (Czech Republic), thus significantly elevating the level of the company's customers’ sourcing security.
Lonza is now capable of rapidly providing the market with additional capacity. As of March the 1st this site will operate as “Lonza Braine”. The post-closing integration activities will commence immediately.
